Prolactinoma
ORPHA:2965DiseaseAutosomal dominantAdolescent, Adult, Childhood, Elderly
Ассоциированные гены3
Фенотипы (HPO)50
Очень частый (80–99%)14
HP:0000026Male hypogonadism
HP:0000044Hypogonadotropic hypogonadism
HP:0000134Female hypogonadism
HP:0000135Hypogonadism
HP:0000140Abnormality of the menstrual cycle
HP:0000141Amenorrhea
HP:0000802Impotence
HP:0000858Irregular menstruation
HP:0000868Decreased fertility in females
HP:0012041Decreased fertility in males
HP:0012503Abnormality of the pituitary gland
HP:0030018Decreased female libido
HP:0100639Erectile dysfunction
HP:0100829Galactorrhea
Частый (30–79%)19
HP:0000529Progressive visual loss
HP:0000771Gynecomastia
HP:0000938Osteopenia
HP:0000939Osteoporosis
HP:0000980Pallor
HP:0002013Vomiting
HP:0002017Nausea and vomiting
HP:0002315Headache
HP:0002615Hypotension
HP:0002920Decreased circulating ACTH level
HP:0003388Easy fatigability
HP:0008240Secondary growth hormone deficiency
HP:0008245Pituitary hypothyroidism
HP:0011362Abnormal hair quantity
HP:0011734Central adrenal insufficiency
HP:0011735Adrenocorticotropin deficient adrenal insufficiency
HP:0011748Adrenocorticotropic hormone deficiency
HP:0012378Fatigue
HP:0030016Dyspareunia
Периодический (5–29%)17
HP:0000508Ptosis
HP:0000618Blindness
HP:0000651Diplopia
HP:0000823Delayed puberty
HP:0000830Anterior hypopituitarism
HP:0000845Elevated circulating growth hormone concentration
HP:0001117Sudden loss of visual acuity
HP:0001250Seizure
HP:0002321Vertigo
HP:0006824Cranial nerve paralysis
HP:0006897Abducens palsy
HP:0007011Fourth cranial nerve palsy
HP:0007942Internal ophthalmoplegia
HP:0012246Oculomotor nerve palsy
HP:0012377Hemianopia
HP:0030517Heteronymous hemianopia
HP:0030521Bitemporal hemianopia
Эпидемиология5
| Тип оценки | Класс распространённости | Среднее (на 100к) | Регион | Квалификация |
|---|---|---|---|---|
| Point prevalence | 1-5 / 10 000 | 44.4 | United Kingdom | Value and class |
| Point prevalence | 6-9 / 10 000 | 62 | Belgium | Value and class |
| Point prevalence | 1-5 / 10 000 | 45.7 | Switzerland | Value and class |
| Annual incidence | 1-9 / 100 000 | 2.05 | Malta | Value and class |
| Point prevalence | 1-5 / 10 000 | 50.7 | Europe | Value and class |
Лекарства и терапия
Источник: Open Targets Platform (в реальном времени)
Клинические исследования
Источник: ClinicalTrials.gov (в реальном времени)